Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.

about

The newly found functions of MTOC in immunological response.Targeted chemo-immunotherapy of leukemia.

P2860

Q38167946-F1B6509D-9592-43ED-BC34-F1EF31DE4613 Q51053221-EE5F8035-1DB7-4D70-8444-A5688E02B8CA

P2860

Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q54475024

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Specific immune responses agai ...... d B in acute myeloid leukemia.

@en

Specific immune responses agai ...... d B in acute myeloid leukemia.

@nl

type

Item

label

Specific immune responses agai ...... d B in acute myeloid leukemia.

@en

Specific immune responses agai ...... d B in acute myeloid leukemia.

@nl

prefLabel

Specific immune responses agai ...... d B in acute myeloid leukemia.

@en

Specific immune responses agai ...... d B in acute myeloid leukemia.

@nl

P1476

Specific immune responses agai ...... d B in acute myeloid leukemia.

@en

P2093

Cornelia Herbst

http://www.w3.org/2001/XMLSchema#string

Jochen Greiner

http://www.w3.org/2001/XMLSchema#string

Marlies Götz

http://www.w3.org/2001/XMLSchema#string

Stephanie Egenrieder

http://www.w3.org/2001/XMLSchema#string

Susanne Hofmann

http://www.w3.org/2001/XMLSchema#string

Vanessa Schneider

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.

The potential role of Aurora kinase inhibitors in haematological malignancies.

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia

P304

1500-1504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.740667

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23101751

http://www.w3.org/2001/XMLSchema#string

Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.

about

P2860

P2860

Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698